Sunday, January 22, 2017 12:19:27 PM
When a new "drug" is tested by the FDA the first concern is to determine if the new drug is harmful. OWCP's products are going to breeze through that stage of testing. Then it goes to efficacy testing. The time spent at that stage is less about "does it work", and more about what ratio of CBD/THC is MOST effective.
In any event, look at the prices of pre clinical biotech companies that have one or two prospects in the pipeline. Those are valued on models that weigh likelihood of FDA approval, likely percent of market share, and scarcity of other medications for that particular ailment.
OWCP will have a complex valuation model because the pipeline is so robust.
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM